Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Predictive Oncology Inc. POAI

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Subsidiary Holds Unique Cancerous Tumor Inventory

Posted on May 29, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI) CEO Dr. Carl Schwartz recently referred to the company’s Helomics subsidiary as a “major asset” during an exclusive NNW interview with Stuart Smith (http://ibn.fm/8knZX). An article discussing the interview reads, “During the interview, Schwartz pointed out that … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Exchanges $2.1M Promissory Note for Common Stock

Posted on May 22, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI) recently entered an agreement with POAI CEO Dr. Carl Schwartz to exchange a $2.1 million promissory note for newly issued equity (http://ibn.fm/lzYPh). An article discussing the company reads, “‘This agreement enables the company to strengthen its … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

Posted on May 22, 2020 by MissionIR

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Vaccine Development Race Through Acquisition, Subsequent Partnership/Licensing of Ground-Breaking Technology

Posted on May 14, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID19 vaccine with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter. According … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) CEO Enters into Debt-to-Equity Agreement, Touts Company’s Major Asset

Posted on May 12, 2020 by MissionIR

POAI CEO exchanges $2.1 million promissory note for newly issued stock shares Strategic agreement enables company to strengthen balance sheet, simplify capital structure in plan to commercialize highly valuable database Because of its unique patient inventory, Helomics is only company … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces At-The-Market Priced $2.2M Registered Direct Offering

Posted on May 7, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates with Dr. Daniel Carter to Enter Race to Develop Potential COVID-19 Vaccine

Posted on May 6, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID-19 vaccine with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter. According … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Streamlines Capital, Simplifies Balance Sheet through Debt Exchange

Posted on May 1, 2020 by MissionIR

POAI CEO exchanges $2.1 promissory note for shares of common stock Agreement enables Predictive Oncology to strengthen balance sheet, simplify capital structure at critical juncture in quest to commercialize highly valuable database POAI cancels outstanding debt of $2,115,000 in aggregate principal amount … Continue reading →

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing CancerQuest2020 Initiative

Posted on April 30, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently reported that its Helomics subsidiary is making headway toward its goal of developing an AI-driven predictive model of ovarian cancer (http://ibn.fm/mENY6). … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Executes Agreement to Exchange $2.1M Debt for Equity

Posted on April 23, 2020 by MissionIR

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Wednesday announced that it has entered into an exchange agreement with POAI chief executive officer Dr. Carl Schwartz regarding a … Continue reading →

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI | Leave a comment